Silence Therapeutics plc

Net Asset Value • Sep 22, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4927K

Silence Therapeutics PLC

22 September 2016

22 September 2016

Notice of Results

London, 22 September 2016 - Silence Therapeutics plc, AIM:SLN ("Silence" or the "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce results for the six months ending 30 June 2016 on Tuesday 27 September 2016.  

Silence Therapeutics plc	Tel: +44 (0)20 3457 6900
Ali Mortazavi, Chief Executive Officer
David Ellam, Chief Financial Officer
Canaccord Genuity Limited (Nominated Adviser and Joint Broker)	Tel: +44 (0)20 7523 8350
Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel
Peel Hunt LLP (Joint Broker)	Tel: +44 (0)20 7418 8900
James Steel/Oliver Jackson
Media Enquiries:	Tel: +44 (0) 20 3727 1000
FTI Consulting
Simon Conway/Brett Pollard/Stephanie Cuthbert

Notes to Editors

About Silence Therapeutics plc

Our technology harnesses the body's natural mechanisms to create therapeutic effects within its cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo. We have developed proprietary modifications to improve the robustness of RNA sequences, as well as advanced chemistries to enhance the effective delivery of therapeutic RNA molecules to target cells.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORGMGZLVMNGVZM